Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 1/20 | 0.47 |
| ▸ | ABL1 | P00519 | 1/20 | 0.43 |
| ▸ | BCR | P11274 | 1/20 | 0.43 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.40 |
| ▸ | SYK | P43405 | 1/20 | 0.36 |
| ▸ | PRMT5 | O14744 | 7/20 | 0.34 |
| ▸ | WDR77 | Q9BQA1 | 7/20 | 0.34 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.34 |
| ▸ | HTR3A | P46098 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.33 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.33 |
| ▸ | RET | P07949 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29407694 | 0.78 | NOTUM (0.46) | NOTUMABL1BCRSYKPRMT5 | |
| SCHEMBL125104 | 0.78 | NOTUM (0.46) | NOTUMABL1BCRSYKCHRNA7 | |
| SCHEMBL23104228 | 0.78 | NOTUM (0.46) | NOTUMABL1BCRSYKCHRNA7 | |
| SCHEMBL130757 | 0.78 | NOTUM (0.46) | NOTUMABL1BCRSYKPRMT5 | |
| SCHEMBL10051003 | 0.78 | PI4KA (0.52) | NOTUMABL1BCRMKNK2PRMT5 | |
| SCHEMBL1092851 | 0.78 | MKNK2 (0.40) | MKNK2PRMT5WDR77TP53 | |
| SCHEMBL12946398 | 0.76 | ADORA2A (0.40) | MKNK2PRMT5WDR77ADORA2AADORA1 | |
| SCHEMBL25066824 | 0.76 | MKNK2 (0.39) | MKNK2PRMT5WDR77 | |
| SCHEMBL25066823 | 0.75 | MKNK2 (0.38) | MKNK2PRMT5WDR77 | |
| SCHEMBL24891601 | 0.75 | MKNK2 (0.38) | MKNK2PRMT5WDR77 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11786534-B2 | Substituted pyrrolo[2,3-d]pyrimidines as EGFR inhibitors | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2023-10-17 | — | — | US | disclosed |
| US-11780843-B2 | Compounds active towards nuclear receptors | NUEVOLUTION A/S (DK) | 2023-10-10 | — | — | US | disclosed |
| US-20230293519-A1 | INTEGRIN INHIBITORS AND USES THEREOF IN COMBINATION WITH OTHER AGENTS | PLIANT THERAPEUTICS INC (US) | 2023-09-21 | — | — | US | disclosed |
| US-20230293519-A1 | INTEGRIN INHIBITORS AND USES THEREOF IN COMBINATION WITH OTHER AGENTS | PLIANT THERAPEUTICS INC (US) | 2023-09-21 | — | — | US | disclosed |
| US-20230183239-A1 | ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE 1 (ENPP-1) INHIBITORS AND USES THEREOF | ABBVIE INC (US) | 2023-06-15 | — | — | US | disclosed |
| WO-2022219636-A1 | ANTI-VIRAL AND ANTI-TUMORAL COMPOUNDS, AND USES THEREOF | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2022-10-20 | — | — | WO | disclosed |
| WO-2022174253-A1 | HPK1 ANTAGONISTS AND USES THEREOF | Nimbus Saturn, Inc. (US) | 2022-08-18 | — | — | WO | disclosed |
| WO-2022135390-A1 | KETOHEXOKINASE INHIBITOR AND USE THEREOF | 四川海思科制药有限公司 | 2022-06-30 | — | — | WO | disclosed |
| US-20220048922-A1 | COMPOUNDS TARGETING PRMT5 | ALIGOS THERAPEUTICS, INC. | 2022-02-17 | — | — | US | disclosed |
| WO-2021084556-A1 | Process for the preparation of tofacitinib and intermediates thereof | AARTI INDUSTRIES LIMITED (IN) | 2021-05-06 | — | — | WO | disclosed |
| US-8450343-B2 | Gamma secretase modulators | SCHERING CORPORATION | 2013-05-28 | — | — | US | disclosed |
| US-8318731-B2 | Pyrrolopyrimidines | JANSSEN PHARMACEUTICA NV (BE) | 2012-11-27 | — | — | US | disclosed |
| US-8309716-B2 | Pyrrolo[2,3-d]pyrimidine derivatives: their intermediates and synthesis | PFIZER INC. (US) | 2012-11-13 | — | — | US | disclosed |
| US-20120259115-A1 | PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES: THEIR INTERMEDIATES AND SYNTHESIS | PFIZER INC. (US) | 2012-10-11 | — | — | US | disclosed |
| US-8232394-B2 | Pyrrolo[2,3-d]pyrimidine derivatives; their intermediates and synthesis | PFIZER INC. (US) | 2012-07-31 | — | — | US | disclosed |
| WO-2012028106-A1 | DEUTERIUM-ENRICHED HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS | ASCEPION PHARMACEUTICALS, INC. (CN) | 2012-03-08 | — | — | WO | disclosed |
| US-20110288297-A1 | Pyrrolo[2,3-d]Pyrimidine Derivatives; Their Intermediates and Synthesis | PFIZER, INC. (US) | 2011-11-24 | — | — | US | disclosed |
| US-20100249145-A1 | Inhibitors of VEGF Receptor and HGF Receptor Signaling | METHYLGENE, INC. | 2010-09-30 | — | — | US | disclosed |
| US-7790729-B2 | Inhibitors of VEGF receptor and HGF receptor signaling | METHYLGENE INC. (CA) | 2010-09-07 | — | — | US | disclosed |
| US-20100204197-A1 | PYRROLOPYRIMIDINES | JANSSEN PHARMACEUTICA NV (BE) | 2010-08-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120259115-A1 | PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES: THEIR INTERMEDIATES AND SYNTHESIS | DPYD, CPS1, TYMS | NOTUM 4332/4885ABL1 1193/4885BCR 3893/4885 |
| US-11780843-B2 | Compounds active towards nuclear receptors | NCOA1, NR1H2, NCOA3 | NOTUM 1837/4885ABL1 3094/4885BCR 1000/4885 |
| US-20230293519-A1 | INTEGRIN INHIBITORS AND USES THEREOF IN COMBINATION WITH OTHER AGENTS | ITGB6, ITGA5, ITGAV | NOTUM 4179/4885ABL1 1324/4885BCR 4232/4885 |
| US-20100249145-A1 | Inhibitors of VEGF Receptor and HGF Receptor Signaling | HGF, MET, FLT1 | NOTUM 4576/4885ABL1 165/4885BCR 1394/4885 |
| US-20100204197-A1 | PYRROLOPYRIMIDINES | PLK4, PLK2, PLK3 | NOTUM 3418/4885ABL1 1020/4885BCR 1638/4885 |
| US-20230183239-A1 | ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE 1 (ENPP-1) INHIBITORS AND USES THEREOF | ENPP1, ENPP3, STING1 | NOTUM 4719/4885ABL1 747/4885BCR 3678/4885 |
| US-20110288297-A1 | Pyrrolo[2,3-d]Pyrimidine Derivatives; Their Intermediates and Synthesis | DPYD, CPS1, TYMS | NOTUM 4247/4885ABL1 1300/4885BCR 3914/4885 |
| US-20220048922-A1 | COMPOUNDS TARGETING PRMT5 | PRMT5, PRMT1, PRMT6 | NOTUM 2048/4885ABL1 288/4885BCR 2042/4885 |
| US-11786534-B2 | Substituted pyrrolo[2,3-d]pyrimidines as EGFR inhibitors | EGFR, ERBB2, ERBB3 | NOTUM 3729/4885ABL1 5/4885BCR 478/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.